Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin

Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2012, Pages 243-250

  Stangier, Joachim ^a,d   Stähle, Hildegard ^b   Rathgen, Karin ^c   Roth, Willy ^a   Reseski, Kathrin ^d,e   Körnicke, Thomas ^d,e  

^a Drug Metabolism and Pharmacokinetics   (Germany)

^b Medical Data Services   (Germany)

^c Clinical Research   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e PAREXEL INTERNATIONAL   (United States)

Author keywords

dabigatran etexilate; digoxin; direct thrombin inhibitor; oral

Indexed keywords

DABIGATRAN ETEXILATE; DIGOXIN; ANTIARRHYTHMIC AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HUMAN EXPERIMENT; INFECTION; INFESTATION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOAVAILABILITY; BLOOD; DRUG EFFECTS; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTI-ARRHYTHMIA AGENTS; ANTITHROMBINS; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PYRIDINES;

EID: 80055121209     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010393342     Document Type: Article

References (21)

1. Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 ; 3: 103-111 (Pubitemid 41647122)
2. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 ; 5: 2179-2185
3. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007 ; 370: 949-956 (Pubitemid 47393577)
4. Wallentin L, Ezekowitz M, Simmers T. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin. Eur Heart J. 2005 ; 26 (suppl). 482
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361: 1139-1151
6. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 ; 361: 2342-2352
7. Ries U, Wienen W. Serine protease as targets for antithrombotic therapy. Drugs Future. 2003 ; 28: 355-370 (Pubitemid 36841172)
8. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 ; 45: 1757-1766 (Pubitemid 34415371)
9. Litonjua R, Penton S, Robinson C, Daubert P. Digoxin: the monarch of cardiac toxicities. J Pharm Pract. 2005 ; 18: 157-168 (Pubitemid 40696234)
10. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G Chest. 8 th edition). Chest. 2008;133(suppl):160-198. 2008: 160-198.
11. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 ; 47: 47-59 (Pubitemid 350260888)
12. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol. 1998 ; 40: 45-46 (Pubitemid 28087270)
13. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 1988 ; 5: 227-244
14. Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med. 2002 ; 9: 1162-1167 (Pubitemid 35291545)
15. Stangier J, Staehle H, Rathgen K, Reseski K, Koernicke T. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin. J Thromb Haemost. 2007 ; 5 ( suppl 2 ):
16. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 ; 3: 103-111 (Pubitemid 41647122)
17. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 1995 ; 92: 1801-1817
18. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol. 1996 ; 28: 155-161 (Pubitemid 26266635)
19. Dell'Orfano JT, Luck JC, Wolbrette DL, Patel H, Naccarelli GV. Drugs for conversion of atrial fibrillation. Am Fam Physician. 1998 ; 58: 471-480 (Pubitemid 28371305)
20. Loo TW, Clarke DM. Merck Frosst Award Lecture 1998: molecular dissection of the human multidrug resistance P-glycoprotein. Biochem Cell Biol. 1999 ; 77: 11-23 (Pubitemid 29342829)
21. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007 ; 64: 292-303 (Pubitemid 47283865)